2,5-Dimethoxy-4-butylamphetamine

DOBU
Clinical data
Other names	DOBU; 2,5-Dimethoxy-4-butylamphetamine; 4-Butyl-2,5-dimethoxyamphetamine
Routes of; administration	Oral
Drug class	Serotonin 5-HT2 receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Pharmacokinetic data
Duration of action	"Very long"
Identifiers
	IUPAC name 1-(4-butyl-2,5-dimethoxyphenyl)propan-2-amine;
CAS Number	63779-89-5 ;
PubChem CID	10060720;
ChemSpider	8236274 ;
UNII	6ARH6DPN4N;
ChEMBL	ChEMBL8214 ;
CompTox Dashboard (EPA)	DTXSID90434976 ;
Chemical and physical data
Formula	C15H25NO2
Molar mass	251.370 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1(=CC(=C(C=C1CC(C)N)OC)CCCC)OC;
	InChI InChI=1S/C15H25NO2/c1-5-6-7-12-9-15(18-4)13(8-11(2)16)10-14(12)17-3/h9-11H,5-8,16H2,1-4H3 ; Key:NGVDYAULSQKEGW-UHFFFAOYSA-N ;
	(verify)

2,5-Dimethoxy-4-butylamphetamine (DOBU) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families related to DOM. It is the derivative of DOM in which the methyl group at the 4 position has been replaced with a butyl group. The drug is taken orally.

It acts as a serotonin receptor agonist, including of the serotonin 5-HT_2A receptor. The drug produces psychedelic-like effects in animals.

DOBU was first described in the literature by Alexander Shulgin in 1970. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).